کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6813657 | 545654 | 2016 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
FSIPSQIASEXC-SSRSPlacebo effect - اثر پلاسبوattention deficit hyperactivity disorder - اختلال کمتوجّهی _ بیشفعالیADHD - بیشفعالیRegression to the mean - رگرسیون به میانگینPittsburgh sleep quality index - شاخص کیفیت خواب در پیتسبورگColumbia Suicide Severity Rating Scale - مقیاس درجه بندی شدت خودکشی در کلمبیاHamilton Depression Rating Scale - مقیاس رتبه بندی افسردگی همیلتونAttention deficit/hyperactivity disorder - کمبود توجه / اختلال بیش فعالی
موضوعات مرتبط
علوم زیستی و بیوفناوری
علم عصب شناسی
روانپزشکی بیولوژیکی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study](/preview/png/6813657.png)
چکیده انگلیسی
The purpose of this study was to examine the efficacy of an extended release guanfacine hydrochloride supplement relative to a placebo supplement in adults (19-62) with ADHD and a sub-optimal response to a stimulant-only treatment program. The study's primary outcome measures were the Attention Deficit Hyperactivity Disorder Rating Scale and the Clinical Global Impression - Severity. Twenty-six adults who met criteria for attention deficit hyperactivity disorder and sub-optimal functioning were randomly assigned to supplement their existing psychostimulant treatment regimen with either a titrated dose (1-6Â mg) of extended release guanfacine hydrochloride or a matching placebo for a 10-week trial. The data were analyzed with standard mixed model analysis of variance procedures, and participants in both the investigational agent group and the placebo group showed statistically significant improvement in their symptoms and functioning over the course of the trial. The treatments did not differ in terms of their efficacy, safety, or tolerability. Although these results do suggest that both treatments were associated with clinical improvement, the possible impacts of socially desirable responding and regression to the mean on these results are discussed.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Psychiatry Research - Volume 236, 28 February 2016, Pages 136-141
Journal: Psychiatry Research - Volume 236, 28 February 2016, Pages 136-141
نویسندگان
Max E. Butterfield, Jaime Saal, Benjamin Young, Joel L. Young,